GLOBAL ALLIANCE OF MENTAL ILLNESS ADVOCACY NETWORKS EUROPE AISBL

Their core work

GAMIAN-Europe is a Brussels-based pan-European patient advocacy network representing people living with mental illness. They bring the patient voice into EU-funded research on psychiatric treatment, eHealth interventions, and health data infrastructure. Their core contribution to research consortia is ensuring that clinical studies and policy initiatives reflect real patient needs and lived experience, particularly in areas like pharmacogenetics and cohort harmonization.

What they specialise in

How they've shifted over time

GAMIAN's H2020 trajectory shows a shift from broad digital health implementation (ImpleMentAll, 2017) toward more specialized clinical and data-driven mental health research. Their middle project (SYNCHROS, 2019) focused on cohort integration and epidemiological data harmonization, while their most recent and largest project (PSY-PGx, 2021) moves into pharmacogenetics — personalising psychiatric medication based on genetic profiles. The trend is clear: from general eHealth advocacy toward precision psychiatry and personalised treatment.

GAMIAN is moving toward personalised medicine in psychiatry, making them a valuable patient-advocacy partner for any consortium working on pharmacogenomics or precision mental health interventions.

How they like to work

GAMIAN operates exclusively as a consortium participant, never as coordinator — consistent with their role as a patient advocacy organization rather than a research-performing institution. With 50 unique partners across 20 countries in just 3 projects, they join large, multi-national consortia where their role is to represent patient interests and facilitate engagement. They are a connector organization: easy to work with, well-networked, and filling a specific niche that research-heavy consortia often need.

Despite only 3 projects, GAMIAN has built a remarkably broad network of 50 partners across 20 countries, reflecting their position in large European consortia. Their Brussels base and pan-European membership give them reach well beyond Belgium.

What sets them apart

GAMIAN-Europe is one of the few pan-European patient advocacy organizations specifically focused on mental illness that actively participates in EU research projects. For any consortium needing a credible, experienced patient representative in psychiatry, mental health, or neurological research, they are an obvious choice. Their growing involvement in pharmacogenetics positions them at the intersection of patient rights and precision medicine — a niche few advocacy organizations occupy.

Highlights from their portfolio

• PSY-PGx
  Their largest project (EUR 209,094) and most specialized — implementing pharmacogenetics in psychiatry represents a significant step into precision medicine advocacy.
• SYNCHROS
  Positioned GAMIAN at the intersection of epidemiological data infrastructure and patient representation, bridging the gap between data scientists and the people whose data feeds cohort studies.
• ImpleMentAll
  Their entry point into H2020, focused on eHealth implementation strategies — established GAMIAN as a credible patient voice in EU digital health research.